PT  - JOURNAL ARTICLE
AU  - Miyamoto, Sho
AU  - Arashiro, Takeshi
AU  - Ueno, Akira
AU  - Kanno, Takayuki
AU  - Saito, Shinji
AU  - Katano, Harutaka
AU  - Iida, Shun
AU  - Ainai, Akira
AU  - Ozono, Seiya
AU  - Hemmi, Takuya
AU  - Hirata, Yuichiro
AU  - Moriyama, Saya
AU  - Kotaki, Ryutaro
AU  - Kinoshita, Hitomi
AU  - Yamada, Souichi
AU  - Shinkai, Masaharu
AU  - Fukushi, Shuetsu
AU  - Takahashi, Yoshimasa
AU  - Suzuki, Tadaki
TI  - Viral load and timing of infection define neutralization diversity to SARS-CoV-2 infection
AID  - 10.1101/2022.06.15.22276432
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.06.15.22276432
4099  - http://medrxiv.org/content/early/2022/06/16/2022.06.15.22276432.short
4100  - http://medrxiv.org/content/early/2022/06/16/2022.06.15.22276432.full
AB  - Immunity to SARS-CoV-2 in COVID-19 cases has diversified due to complex combinations of exposure to vaccination and infection. Elucidating the drivers for upgrading neutralizing activity to SARS-CoV-2 in COVID-19 cases with pre-existing immunity will aid in understanding immunity to SARS-CoV-2 and improving COVID-19 booster vaccines with enhanced cross-protection against antigenically distinct variants. This study revealed that the magnitude and breadth of neutralization responses to SARS-CoV-2 infection in breakthrough infections are determined by upper respiratory viral load and vaccination-infection time interval, but not by the lineage of infecting viruses. Notably, the time interval, but not the viral load, may play a critical role in expanding the breadth of neutralization to SARS-CoV-2. This illustrates the importance of dosing interval optimization in addition to antigen design in the development of variant-proof booster vaccines.One-Sentence Summary Viral load and infection timing define the magnitude and breadth of SARS-CoV-2 neutralization after breakthrough infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Japanese Society for the Promotion of Science Grants-in-Aid for Scientific Research (JSPS KAKENHI) grant 21K20768 (SMiyamoto), and Japan Agency for Medical Research and Development (AMED) grant JP21fk0108104 (TS), JP22fk0108637 (TS), JP20fk0108534 (YT), JP21fk0108615 (YT). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Medical Research Ethics Committee of National Institute of Infectious Diseases gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors